Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - atropine sulfate - solution for injection in a pre-filled syringe - atropine sulfate 0.1 mg/ml - drugs for functional gastrointestinal disorders

Ireland - English - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - atropine sulfate - solution for injection - 600 microgram(s)/millilitre - belladonna alkaloids, tertiary amines; atropine

United States - English - NLM (National Library of Medicine)

sebela pharmaceuticals inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), difenoxin hydrochloride (unii: vqz63k01iw) (difenoxin - unii:3zz5bj9f2q) - atropine sulfate 0.025 mg - motofen® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea. motofen® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic e. coli, salmonella species, shigella ) and pseudomembranous colitis associated with broad spectrum antibiotics. antiperistaltic agents should not be used in the conditions because they may prolong and/or worsen diarrhea. motofen® is contraindicated in children under 2 years of age because of the decreased margin of safety of drugs in this class in younger age groups. motofen® is contraindicated in patients with a known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced. motofen® tablets are a schedule iv controlled substance. addiction to (dependence on) difenoxin hydrochloride is theoretically possible at high dosage. therefore, the recommended dosage should not be e

Canada - English - Health Canada

pfizer canada ulc - atropine sulfate - solution - 1mg - atropine sulfate 1mg - antimuscarinics antispasmodics

United States - English - NLM (National Library of Medicine)

apotex corp. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate ophthalmic solution, 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. pregnancy category c: there are no adequate and well-controlled studies of atropine sulfate in pregnant women. animal development and reproduction studies have not been conducted with atropine sulfate. since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. traces of atropine have been found in human milk following administration of atropine solution for injection. because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution, 1% is administered to a nursing woman. due to the potential for systemic absorption of atropine sulfate ophthalmic solution, the use of atropine sulfate ophthalmic solution, 1% in children under the age of 3 months is not recommended and the use in children under 3 years of age should be limited to no more than one drop per eye per day. no overall differences in safety and effectiveness have been observed between elderly and younger adult patients.

United States - English - NLM (National Library of Medicine)

akorn - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate ophthalmic solution, usp 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. pregnancy category c: there are no adequate and well-controlled studies of atropine sulfate in pregnant women. animal development and reproduction studies have not been conducted with atropine sulfate. since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, usp 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. traces of atropine have been found in human milk following administration of atropine solution for injection. because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution, usp 1% is administered to a nursing woman. due to the potential fo

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - 1. in the treatment of parkinsonism. rigidity and tremor relieved by the apparently selective depressant action. 2. in the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. 3. to relieve hypertonicity of the uterine muscle. 4. to relax the spasm of biliary and uretered colic and bronchial spasm. 5. to diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. 6. to control the crying and laughing episodes in patients with brain lesions. 7. in cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal eeg patterns, stupor and neurological signs. 8. in the management of peptic ulcer. 9. in anesthesia to control excessive salivation and bronchial secretions. 10. to control rhinorrhea of acute rhinitis or hay fever. 11. as an antidote for pilocarpine, physostigmine,

United States - English - NLM (National Library of Medicine)

avpak - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - for mydriasis and/or cycloplegia. for cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract. this product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma. this product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine. this product should not be used in those persons showing hypersensitivity to any component of this preparation.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - atropine sulfate monohydrate, quantity: 600 microgram/ml; sodium hydroxide - injection, solution - excipient ingredients: water for injections; sodium chloride; sulfuric acid - indications as at 30 september 2003:surgery : atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. the use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. after surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. cardiopulmonary resuscitation : atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. anticholinesterase poisoning : atropine juno is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, amanita muscaria mushrooms or other compounds with anticholinesterase activity. a cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoire aguettant - atropine sulfate - solution for injection in pre-filled syringe - 0.2 milligram(s)/millilitre - belladonna alkaloids, tertiary amines; atropine